The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Sporadic inclusion body myositis (sIBM) presents with a characteristic clinical phenotype of slow-onset weakness and atrophy, affecting proximal and distal limb muscles and facial and pharyngeal ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

sIBM is a complex disorder, the underlying cause of which is unclear. The observation that the intact muscle fibers are invaded by T lymphocytes, whereas the vacuolated fibers lack T-cell ...